Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$123.81
+2.7%
$132.98
$99.92
$141.23
$209.67B0.736.25 million shs19.57 million shs
C.R. Bard Inc stock logo
BCR
C.R. Bard
$331.24
$0.00
$222.42
$337.73
N/AN/A679,456 shsN/A
Boston Scientific Corporation stock logo
BSX
Boston Scientific
$103.68
-0.9%
$103.42
$71.88
$107.53
$154.82B0.686.76 million shs8.57 million shs
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
$518.62
+0.5%
$535.90
$425.00
$616.00
$185.00B1.641.68 million shs1.90 million shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abbott Laboratories stock logo
ABT
Abbott Laboratories
+2.53%-6.17%-6.45%-5.49%+18.24%
C.R. Bard Inc stock logo
BCR
C.R. Bard
0.00%0.00%0.00%0.00%0.00%
Boston Scientific Corporation stock logo
BSX
Boston Scientific
-0.90%+0.50%+2.29%+9.05%+33.92%
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
+0.48%+1.28%+1.79%+7.43%+21.68%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Abbott Laboratories stock logo
ABT
Abbott Laboratories
4.988 of 5 stars
3.45.04.24.53.22.52.5
C.R. Bard Inc stock logo
BCR
C.R. Bard
N/AN/AN/AN/AN/AN/AN/AN/A
Boston Scientific Corporation stock logo
BSX
Boston Scientific
4.6982 of 5 stars
3.63.00.04.23.92.51.3
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
4.7028 of 5 stars
3.43.00.04.03.52.51.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Abbott Laboratories stock logo
ABT
Abbott Laboratories
2.82
Moderate Buy$144.4716.69% Upside
C.R. Bard Inc stock logo
BCR
C.R. Bard
0.00
N/AN/AN/A
Boston Scientific Corporation stock logo
BSX
Boston Scientific
3.13
Buy$116.0911.97% Upside
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
2.70
Moderate Buy$592.8614.32% Upside

Current Analyst Ratings Breakdown

Latest BCR, ABT, ISRG, and BSX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/18/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$147.00 ➝ $142.00
7/18/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$142.00 ➝ $141.00
7/18/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$148.00 ➝ $145.00
7/18/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$143.00 ➝ $145.00
7/16/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$130.00 ➝ $140.00
7/15/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$145.00 ➝ $147.00
7/15/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$127.00 ➝ $137.00
7/14/2025
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$566.00
7/8/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$140.00 ➝ $145.00
7/8/2025
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetIn-Line ➝ In-Line$470.00 ➝ $550.00
6/16/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$41.95B5.13$6.76 per share18.31$27.62 per share4.48
C.R. Bard Inc stock logo
BCR
C.R. Bard
N/AN/AN/AN/AN/AN/A
Boston Scientific Corporation stock logo
BSX
Boston Scientific
$17.55B8.74$3.62 per share28.67$14.93 per share6.94
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
$8.35B22.26$8.03 per share64.61$46.41 per share11.17
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$13.40B$7.7115.5221.612.2932.43%18.83%10.88%N/A
C.R. Bard Inc stock logo
BCR
C.R. Bard
N/A$15.1221.91N/AN/AN/AN/AN/A
Boston Scientific Corporation stock logo
BSX
Boston Scientific
$1.85B$1.3775.6832.102.7211.58%18.67%10.38%7/23/2025 (Estimated)
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
$2.32B$6.8276.0467.975.4728.41%14.43%12.81%7/22/2025 (Estimated)

Latest BCR, ABT, ISRG, and BSX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/23/2025Q2 2025
Boston Scientific Corporation stock logo
BSX
Boston Scientific
$0.72N/AN/AN/A$4.89 billionN/A
7/22/2025Q2 2025
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
$1.92N/AN/AN/A$2.35 billionN/A
7/17/2025Q2 2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$1.26$1.26N/A$1.01$11.01 billion$11.14 billion
4/23/2025Q1 2025
Boston Scientific Corporation stock logo
BSX
Boston Scientific
$0.67$0.75+$0.08$0.45$4.57 billion$4.66 billion
4/22/2025Q1 2025
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
$1.71$1.81+$0.10$1.92$2.19 billion$2.25 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$2.361.91%N/A30.61%54 Years
C.R. Bard Inc stock logo
BCR
C.R. Bard
$0.780.24%N/A5.16%N/A
Boston Scientific Corporation stock logo
BSX
Boston Scientific
N/AN/AN/AN/AN/A
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
N/AN/AN/AN/AN/A

Latest BCR, ABT, ISRG, and BSX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/13/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
quarterly$0.591.73%7/15/20257/15/20258/15/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Abbott Laboratories stock logo
ABT
Abbott Laboratories
0.26
1.78
1.27
C.R. Bard Inc stock logo
BCR
C.R. Bard
N/AN/AN/A
Boston Scientific Corporation stock logo
BSX
Boston Scientific
0.47
1.45
0.88
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
N/A
4.98
3.97

Institutional Ownership

CompanyInstitutional Ownership
Abbott Laboratories stock logo
ABT
Abbott Laboratories
75.18%
C.R. Bard Inc stock logo
BCR
C.R. Bard
79.11%
Boston Scientific Corporation stock logo
BSX
Boston Scientific
89.07%
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
83.64%

Insider Ownership

CompanyInsider Ownership
Abbott Laboratories stock logo
ABT
Abbott Laboratories
0.46%
C.R. Bard Inc stock logo
BCR
C.R. Bard
0.80%
Boston Scientific Corporation stock logo
BSX
Boston Scientific
0.50%
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
0.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Abbott Laboratories stock logo
ABT
Abbott Laboratories
114,0001.74 billion1.73 billionOptionable
C.R. Bard Inc stock logo
BCR
C.R. Bard
N/AN/AN/ANot Optionable
Boston Scientific Corporation stock logo
BSX
Boston Scientific
53,0001.48 billion1.47 billionOptionable
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
15,638358.42 million355.91 millionOptionable

Recent News About These Companies

Intuitive opens manufacturing plant in Bulgaria
Leerink Partnrs Issues Optimistic Outlook for ISRG Earnings
BTIG Sticks to Their Buy Rating for Intuitive Surgical (ISRG)
Intuitive demonstrates telesurgery capabilities

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Abbott Laboratories stock logo

Abbott Laboratories NYSE:ABT

$123.81 +3.30 (+2.74%)
Closing price 07/18/2025 03:59 PM Eastern
Extended Trading
$123.80 -0.01 (-0.01%)
As of 07/18/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

C.R. Bard stock logo

C.R. Bard NYSE:BCR

C. R. Bard, Inc. (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis. Its vascular products cover a range of minimally invasive devices for the treatment of peripheral vascular disease and end-stage renal disease. Its urology products include basic urology drainage products, fecal and urinary continence products, urological specialty products and Targeted Temperature Management products. Its oncology products cover a range of devices used in the treatment and management of various cancers, and other diseases and disorders. Its surgical specialty products include implanted patches and fixation devices for hernia and soft tissue repairs.

Boston Scientific stock logo

Boston Scientific NYSE:BSX

$103.68 -0.97 (-0.93%)
Closing price 07/18/2025 03:59 PM Eastern
Extended Trading
$103.63 -0.05 (-0.05%)
As of 07/18/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Intuitive Surgical stock logo

Intuitive Surgical NASDAQ:ISRG

$518.62 +2.46 (+0.48%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$518.85 +0.23 (+0.04%)
As of 07/18/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. The company sells its products through direct sales organizations, such as capital and clinical sales teams. It has a collaboration agreement with FluoGuide A/S for head & neck cancer. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.